Pazopanib

VOTRIENT®

Antineoplastic landscape

About VOTRIENT®

  1. Marketed by Novartis Pharmaceuticals Corporation (United States and European Union) and GlaxoSmithKline plc (Japan)
  2. Selective multi-targeted receptor tyrosine kinase inhibitor
  3. Treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma

Approvals

  1. First E.U. approval: June 14, 2010
  2. First U.S. approval: October 19, 2009

Constraint date forecast:

  1. Patent expiry: 2023 (United States)
  2. SPC expiries: 2025 (European Union)
  3. Patent expiry: 2027 (Japan)

The future of the generics landscape

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team